Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Stock Analysis

Kyron Capital Group (ASX:KYN) Share Price Drops: Key Reasons Explained

In its 28 August 2026 announcement, Kyron reported funds management income of $27.1 million against $47.1 million, corporate costs of $25.0 million against $37.1 million and a coreEarningsloss of $30.3 million against $8.9 million, driven by legacy financing costs, provisions against managed fund loans …

Sonal Goyal | 27 October 2026

Thorney Technologies (ASX:TEK) Shares Drop on the ASX: What’s Driving the Move?

The Appendix 4E reported a loss from investment activities of $7.472 million against a profit of $2.823 million, a loss before tax of $9.709 million against a profit of $341,000 and a loss after tax of $16.410 million against a loss of $4.662 million. …

Sonal Goyal | 27 October 2026

Alterity Therapeutics (ASX:ATH) Shares Fall: What’s Behind the Drop?

The audited Appendix 4E reportedRevenueof $1,716,656, up 284.7%, which is interest received on bank accounts, and a net loss after tax of $23,400,949, up 92.6% from $12,147,828. Cash was $37,317,962 at 30 June 2026, against $33,158,642 a year earlier.

Sonal Goyal | 27 October 2026

Botanix Pharmaceuticals (ASX:BOT) Shares Slide as Quarterly Report Details Cost Actions

In its 27 October 2026 report, Botanix said prescriptions shipped grew 5.3% to 35,130 from 33,358 in Q4 FY26, following a resizing of the sales force from 50 to 39 completed on 31 July 2026. Average gross-to-netYieldwas 21% against 22%, which the company attributed …

Sonal Goyal | 27 October 2026

BTC Health (ASX:BTC) Shares Fall as Supplier Arna Pharma Update Is in Focus

In its 8 September 2026 announcement, BTC Health said Arna Pharma was placed into voluntary administration on 7 September 2026 after its board appointed administrators. Arna makes Bronchitol and Aridol, both TGA-registered, with Bronchitol listed on the Pharmaceutical Benefits Scheme, and both are manufactured …

Sonal Goyal | 27 October 2026

Invex Therapeutics (ASX:IXC) Stock Takes a Hit — Here’s Why

In its release dated 26 October 2026, Invex said it signed a binding agreement to acquire 100% of Rekover Therapeutics Limited, a New Zealand company repurposing nalfurafine for demyelinating diseases, including chronic optic neuropathy in patients with multiple sclerosis. Rekover designed REVIVE, a Phase …

Sonal Goyal | 27 October 2026

Lumos Diagnostics (ASX:LDX) Shares Fall as Quarterly Update and FebriDx Study Details Land

In its 27 October 2026 statement, Lumos said 265 healthcare sites across 29 states were actively ordering FebriDx as of 11 October 2026, up from 215 sites on 15 September and 170 on 26 July. Evaluations are under way at 485 sites, up from …

Sonal Goyal | 27 October 2026

Argent BioPharma (ASX:RGT) Shares Fall as Cannabis Genetics Licence Is Announced

In its 27 October 2026 announcement, Argent said the agreement covers four proprietary genotypes (MXC-THC-10/3, MXC-THC-81/5, MXC-THC-40/3 and MXC-THC-40/2) and gives Thai Phytomed International exclusive worldwide rights to cultivate, process, extract, manufacture, market, distribute,Importand export the genetics and derived products, subject to regulatory requirements. …

Sonal Goyal | 27 October 2026

Resonance Health (ASX:RHT) Shares Fall as Investors React to Latest News

In its October 2026 presentation, Resonance Health reported FY26 revenue of $15.8 million, up 42% on FY25, normalised EBITDA of $2.6 million (a 16% margin) and statutory net profit after tax of $1.5 million. Operating cash inflow was $2.9 million, and net cash was …

Sonal Goyal | 27 October 2026

Vectus Biosystems (ASX:VBS) Stock Under Pressure: What Investors Should Know

In its 30 September 2026 announcement, Vectus said the US FDA granted its request for a pre-Investigational New Drug Type B meeting on its proposed development program for VB0004 in idiopathic pulmonary fibrosis. The FDA’s written responses are expected by mid-November 2026, and the …

Sonal Goyal | 27 October 2026
Support

Hi! How can we help you today?

Loading…